Lack of effectiveness of Bebtelovimab monoclonal antibody among high-risk patients with SARS-Cov-2 Omicron during BA.2, BA.2.12.1 and BA.5 subvariants dominated era

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariants are expected to be resistant to Bebtelovimab (BEB) monoclonal antibody (MAb) and the real-world experience regarding its effectiveness is scarce. This retrospective cohort study reports a data analysis in Banner Healthc...

Descripción completa

Detalles Bibliográficos
Autores principales: Sridhara, Srilekha, Gungor, Ahmet B., Erol, Halil K., Al-Obaidi, Mohanad, Zangeneh, Tirdad T., Bedrick, Edward J., Ariyamuthu, Venkatesh K., Shetty, Aneesha, Qannus, Abd A., Mendoza, Katherine, Murugapandian, Sangeetha, Gupta, Gaurav, Tanriover, Bekir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10146441/
https://www.ncbi.nlm.nih.gov/pubmed/37115780
http://dx.doi.org/10.1371/journal.pone.0279326

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10146441/
https://www.ncbi.nlm.nih.gov/pubmed/37115780
http://dx.doi.org/10.1371/journal.pone.0279326

Ejemplares similares